![PKMYT1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer](https://oncodaily.com/pub/uploads/2024/09/images-13.png)
Photo of Khandan Keyomarsi taken from faculty.mdanderson.org
Sep 3, 2024, 10:55
PKMYT1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer
Khandan Keyomarsi shared on X:
“Exciting work from our lab reporting that TNBCs that do not respond to chemotherapy have high LMW-E levels that upregulates and stabilizes PKMYT1, leading to enhanced p-CDK1 in TNBCs, which are now more sensitive to the PKMYT1 inhibitor RP-6306.”
Amriti R. Lulla
Asha S. Multani
Aysegul Sahin
Breast Cancer
C. Gary. Marshall
cancer
Cansu Karakas
Fuchenchu Wang
Kelly K. Hunt
Khandan Keyomars
Khandan Keyomarsi
Marc A. Pina
Mei-Kuang Chen
Mi Li
Natalie W. Fowlkes
OncoDaily
Oncology
PKMYT1 inhibitor
Sofia Mastoraki
Spyros Tsavachidis
Tuyen D.T. Nguyen
Tuyen N. Bui
Yan Wang
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2024, 10:55